DENTSPLY SIRONA (XRAY) shares have been in focus after quarterly results that combined higher fourth quarter sales and a smaller net loss with an earnings miss, a cautious 2026 outlook, and sizeable impairment charges tied to softer U.S. demand.

The earnings miss, sizeable impairments and cautious 2026 sales guidance have fed into recent volatility, with a 1-day share price return of 4.43% decline and a 7-day share price return of 10.97% decline, even as the 90-day share price return of 14.67% suggests earlier momentum that contrasts with a 1-year total shareholder return of 16.74% decline and deeper long term losses.

If this kind of earnings driven swing has you reassessing your watchlist, it could be worth scanning our list of 32 healthcare AI stocks as another way to look for opportunities in healthcare related growth themes.

With the share price under pressure despite a value score of 5 and a reported intrinsic discount of about 65%, the key question is whether this reflects a genuine margin of safety or if the market is already discounting any future recovery.

Most Popular Narrative: 11.7% Undervalued

With DENTSPLY SIRONA closing at $12.74 against a widely followed fair value estimate of $14.43, the current setup centers on modest implied upside and a detailed earnings recovery path.

Active cost reduction programs, operational streamlining, and supply chain optimization are in progress, with management indicating a stronger urgency to go "deeper and faster," potentially boosting EBITDA margin and cash flow generation through both lower SG&A and more efficient manufacturing.

Want to see how a modest sales outlook, a sharp profitability swing, and a reset earnings multiple are stitched together into one target price? The full narrative lays out the revenue assumptions, margin rebuild, and future P/E needed to back that $14.43 fair value without leaving the key moving parts to guesswork.

Result: Fair Value of $14.43 (UNDERVALUED)

However, you also need to keep an eye on weak U.S. sales and rising tariff related costs, which could pressure margins and undermine any earnings recovery story.

Next Steps

If this mix of pressure and potential has you on the fence, take a closer look at the underlying data now and shape your own view. Start with 3 key rewards and 1 important warning sign.

Ready to hunt for more ideas?

If this earnings story has sharpened your focus, do not stop here. Broaden your watchlist with a few hand picked ideas from our screeners.

• Target potential value opportunities by scanning our 50 high quality undervalued stocks that currently stand out against their fundamentals.
• Prioritise resilience by checking out 66 resilient stocks with low risk scores that score well on our risk checks.
• Get ahead of the crowd by reviewing a screener containing 24 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.